- Home
- LKSP vs CHRS Comparison
LKSP vs CHRS Comparison
Compare LKSP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$1.16
Company Overview
Basic Information| Metric | LKSP | CHRS |
|---|---|---|
| Founded | 2024 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.3M | 177.7M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LKSP | CHRS |
|---|---|---|
| Price | $10.25 | $1.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 11.4K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 472.00 |
| EPS | ★ 0.09 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $44.19 |
| Revenue Next Year | N/A | $65.06 |
| P/E Ratio | $113.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.90 | $1.09 |
| 52 Week High | $10.25 | $2.62 |
Technical Indicators
Market Signals| Indicator | LKSP | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 72.70 | 43.48 |
| Support Level | $10.09 | N/A |
| Resistance Level | N/A | $1.53 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 100.00 | 30.30 |
Price Performance
Historical Comparison LKSP
CHRS
About LKSP Lake Superior Acquisition Corp. Class A Ordinary Shares
Lake Superior Acquisition Corp is a blank check company.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.